Longevity Vision Holding

The firm invests exclusively in the longevity sector — companies that use artificial intelligence and biotechnology to extend human healthspan. Its thesis holds that aging is the primary driver of the most burdensome diseases, and that venture-scale returns are achievable by funding interventions that measure biological age, clear senescent cells, or reprogram cellular function. The firm views aging as a treatable condition rather than an immutable process, a stance that aligns it with a small set of dedicated longevity investors.

The firm deploys capital from seed through late-stage venture, with early-stage investments forming the core of its activity. It leads and co-leads rounds, often alongside specialized health-tech and biotech funds. The stage-agnostic approach allows it to support companies from preclinical validation through clinical trials and toward regulatory approval, though follow-on investments depend on milestone achievement.

The firm does not invest in generalist health-tech, traditional biotech without an aging component, or therapeutic areas unrelated to age-related disease. It also avoids sectors such as enterprise software, fintech, and consumer internet that fall outside its longevity mandate. This sector exclusion is structural — the firm positions itself as a pure-play investor, and any diversification into non-longevity areas would dilute its stated thesis.

The firm's known activity is primarily direct equity investments in operating companies. There is no public record of it acting as a fund-of-funds or making limited partner commitments to other venture managers. The deal-by-deal structure is consistent with early-stage venture firms that prefer concentrated exposure and direct governance rights in their portfolio companies.

The firm sources deals through academic research networks in aging biology, longevity-focused venture conferences, and co-investor relationships with specialized health-tech funds. Key sourcing hubs include Boston, the San Francisco Bay Area, and Israel, where academic institutions produce a disproportionate share of longevity-related spinouts. The firm's concentrated thesis acts as a filtering mechanism, attracting founders who seek investors fluent in the scientific and regulatory challenges of aging interventions.